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ABSTRACT
To gain insight into the mechanisms by which
the Myb transcription factor controls normal hem-
atopoiesis and particularly, how it contributes to
leukemogenesis, we mapped the genome-wide
occupancy of Myb by chromatin immunopre-
cipitation followed by massively parallel sequencing
(ChIP-Seq) in ERMYB myeloid progenitor cells. By
integrating the genome occupancy data with whole
genome expression profiling data, we identified a
Myb-regulated transcriptional program. Gene signa-
tures for leukemia stem cells, normal hematopoietic
stem/progenitor cells and myeloid development
were overrepresented in 2368 Myb regulated
genes. Of these, Myb bound directly near or within
793 genes. Myb directly activates some genes
known critical in maintaining hematopoietic stem
cells, such as Gfi1 and Cited2. Importantly, we
also show that, despite being usually considered
as a transactivator, Myb also functions to repress
approximately half of its direct targets, including
several key regulators of myeloid differentiation,
such as Sfpi1 (also known as Pu.1), Runx1, Junb
and Cebpb. Furthermore, our results demonstrate
that interaction with p300, an established coactiv-
ator for Myb, is unexpectedly required for Myb-
mediated transcriptional repression. We propose
that the repression of the above mentioned key
pro-differentiation factors may contribute essen-
tially to Myb’s ability to suppress differentiation
and promote self-renewal, thus maintaining pro-
genitor cells in an undifferentiated state and
promoting leukemic transformation.
INTRODUCTION
The Myb transcription factor is a master regulator of
normal hematopoiesis (1). It is required for the establish-
ment of deﬁnitive hematopoiesis as evidenced by the early
embryonic death of Myb null mice due to severe anemia
with profound defects in the development of multiple
other lineages (2). Moreover, Myb has been shown to
play an essential role in maintaining adult hematopoietic
stem cells (HSC) using a conditional Myb knockout
mouse model (3).
Myb also contributes actively to leukemogenesis.
Activated Myb induces leukemias in chickens and mice
(4,5). Importantly, MYB was found to be activated in
human leukemias by genetic lesions, such as translocation,
duplication (6–11) and structural alteration (12). Myb is
also required for leukemic transformation by other onco-
genes, such as MLL-ENL (13) and BCR-ABL (14).
Myb’s oncogenic activities stem primarily from its
ability to suppress differentiation and promote self-
renewal. Enforced expression of wild-type or activated
Myb can block the induced differentiation of established
immature, myeloid progenitor-like cell lines (15–17)
and can generate such lines from primary myeloid cells
(18). Conversely, siRNA-mediated knockdown of MYB
induces a phenotype mimicking differentiation induced
by phorbol ester in THP-1 myeloid leukemia cell line
(19). Similarly to its role in normal HSCs, Myb plays a
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population, at least in MLL translocation-induced leuke-
mias (20).
Myb regulates normal hematopoiesis and leukemo-
genesis by directing orchestrated expression of its tran-
scriptional targets. Although more than 80 genes have
been reported to be targeted by Myb [(1); see also
Supplementary Table S1 and references therein], many
of them have not been thoroughly validated for in vivo
DNA occupancy by Myb. Most importantly, the current
repository of Myb target genes does not adequately
explain the key elements of Myb’s transforming activity,
namely suppressing differentiation and promoting self-
renewal.
Here we report the transcriptional program instigated
by Myb in a myeloid progenitor cell line model. We
identiﬁed Myb target genes by integrating dynamic
genome-wide data from ChIP-Seq with that from global
gene expression proﬁling. Importantly, we uncovered that,
despite being usually considered as a transactivator, Myb
also functions to directly repress many target genes,
including several master regulators of the myeloid
lineage, suggesting that this hitherto unappreciated role
of Myb may constitute a crucial part of its oncogenic
activity. We also showed that the interaction with p300,
a known Myb co-activator, is required for both repression
and activation by Myb. Thus our results indicate that
Myb controls a transcriptional program critical for
myelopoiesis and leukemogenesis through both positive
and negative transcriptional regulation.
MATERIALS AND METHODS
Cell culture and bone marrow progenitor isolation and
transduction
The withdrawal and re-addition of b-E2 from ERMYB
cells (21) was performed as described (22). Separation
and retroviral transduction of mouse primary bone
marrow cells was conducted as described (15). Brieﬂy,
c-Kit
high progenitors were enriched from C57BL/6 mice
bone marrow cells using EasySep mouse CD117 (c-Kit)
positive selection kit (StemCell) and transduced with
retroviruses encoding wt-Myb, CT3-Myb or L302A.
CT3-Myb. Cells were cultured in Isocove’s modiﬁed
Dulbecco’s medium supplemented with 10% fetal bovine
serum (Hyclone) and 60 FDU/ml GM-CSF for 7 days,
and subsequently FACS-sorted for GFP expression
(encoded by the retroviral vector) before harvest.
To isolate granulocyte-macrophage progenitors
(GMPs) (Lin
  c-Kit
+ Sca1
  CD16/32
high CD34
high) (23),
bone marrow cells of 8 week-old wild-type C57BL/6 or
‘booreana’ (24) mice were enriched for c-Kit expressing
cells using CD117 microbeads on an autoMACS cell sep-
arator (Miltenyi). Lineage depletion was performed with
unconjugated lineage monoclonal antibody cocktail
against CD3e, CD4, CD5, CD8, B220, Gr1, CD11b and
Ter119 and PE-conjugated donkey anti-rat IgG. GMPs
were identiﬁed by a combination of Sca1-PerCP-Cy5.5,
cKit-PE-Cy7, CD34-FITC, CD16/32-APC. All antibodies
were from eBioscience.
Gene expression proﬁling analysis
Triplicate total RNA samples from ERMYB cells were
collected at 0, 6 and 24h after b-E2 withdrawal and 6h
after b-E2 re-addition. RNA quality was examined on
Agilent 2100 Bioanalyzer using Eukaryote Total RNA
Nano chips. Samples were then analyzed by Illumina
Mouse Whole Genome arrays (WG6). Probe intensities
were corrected and normalized by the Lumi package
(25). Differentially expressed genes (B statistic >1
between any two consecutive time points) were identiﬁed
by the LIMMA package (26) and then grouped into dif-
ferent classes according to their kinetic proﬁles as follows.
Class A genes (likely Myb target genes) manifested four
expression proﬁles, classiﬁed by the changes in expression
level between the four time-points, consistent with Myb
activity: nfp (negative-flat-positive) and nnp (negative-
negative-positive) proﬁles for Myb activated genes and
pfn (positive-flat-negative) and ppn (positive-positive-
negative) proﬁles for Myb repressed genes. Proﬁles for
class B genes (possible Myb target genes) included four
for Myb activated genes (fnp, ffp, nff and nnf) and four
for Myb repressed genes (fpn, ffn, pff and ppf). These class
B proﬁles deviated from the class A ones but show at least
one signiﬁcant response to b-E2 withdrawal or re-addition.
Simpliﬁed arrow diagrams representing these dynamic
expression proﬁles are shown in 1C (for Class A) and
Supplementary Figure S1 (for Class B). Class C is
comprised of genes that were differentially expressed but
without assignable proﬁles, genes with no signiﬁcant dif-
ferential expression throughout the time course, and genes
not detectably expressed (all samples have a detection
P>0.01) in ERMYB cells at any time point.
Normalized expression levels of Myb regulated genes
(classes A and B) were visualized using the Hierarchical
Clustering module of GenePattern package (27).
TaqMan low density qPCR arrays and TaqMan assays
Custom TaqMan low density qPCR arrays (TLDAs)
(96a format, Applied Biosystems) were made to order
containing a total of 89 candidate Myb target genes
(Supplementary Tables S3 and S4). Assays were carried
out as per manufacturer’s instructions. Expression was
normalized to the ‘housekeeping’ gene Hprt1.
Individual inventoried TaqMan assays (Applied
Biosystems) were used to measure expression of identiﬁed
Myb-activated and Myb-repressed genes in mouse GMPs.
ChIP and ChIP-Seq
ChIP was performed as described (28). ERMYB cells were
harvested in the presence of b-E2 or 6h after b-E2 with-
drawal. After formaldehyde ﬁxation, chromatin was frag-
mented to 200–800bp by sonication. ER Ab-10 (Clone
TE111.5D11, NeoMarkers) which recognizes the ERa
ligand binding domain of the ER-Myb fusion protein, or
mouse IgG1 isotype control (02-6100, Zymed) was used
with ERMYB cells. Alternatively, the anti-CT5 (29) and
Thelma anti-Myb (30) sera (mixed 1:1) were used. Pooled
Myb 1-1 antibody (05-175, Upstate) and Thelma
anti-Myb sera (30) (mixed 1:1) were used with ChIP in
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p300 (sc-585, Santa Cruz), anti-CBP (sc-369, Santa Cruz),
anti-acetyl-Histone 3 (06-599, Upstate), anti-H3K4me1
(ab8895, Abcam), anti-H3K4me3 (07-473, Upstate),
anti-H3K9me3 (ab8898, Abcam), anti-H3K27me3
(07-449, Upstate) and rabbit IgG (02-6102, Zymed).
Primers for ChIP-qPCR are described in Supplementary
Table S10.
For ChIP-Seq, biological duplicate ChIP samples were
prepared using ER-10 antibody from ERMYB cells
cultured in the presence of b-E2 (+b-E2 or
‘activated’-Myb) or deprived of b-E2 for 6h ( b-E2 or
‘inactivated’-Myb). The employment of the ER antibody
rather than Myb antibody raised the potential concern
that a subset of identiﬁed Myb binding regions (MBRs)
might be occupied by ERa rather than the Myb fusion
protein. However, our results indicate this is unlikely to
be the case. Almost all examined MBRs which were
validated using ER antibody have also been validated
using mixed anti-Myb sera. Furthermore, almost all of
a set of conserved MBRs have been validated in human
HL-60 cells using pooled MYB antibodies (Figure 3C).
Moreover, the canonical ER binding motif was not
detected in the de novo motif discovery analysis
(Supplementary Figure S2C). Similar concerns about
the Myb regulated genes identiﬁed by expression proﬁling
in ERMYB cells are allayed by the fact that very few of
these showed signiﬁcant expression changes in response
to b-E2 in a cell line derived by transformation with
non-ER-fused, constitutively activate CT3-Myb (A69
cells; Supplementary Table S2). Moreover, our Myb-
regulated gene set showed no signiﬁcant overlap with
the well-established estrogen-response signature (data
not shown), and furthermore, the majority of a set
of identiﬁed Myb regulated genes have been validated
independently in Myb transduced primary bone marrow
cells (Figure 1D and Supplementary Table S4).
ChIP-Seq DNA libraries were prepared using the
Illumina ChIP-Seq Sample Prep Kit, then quality-checked
and quantiﬁed on Agilent 2100 Bioanalyzer using
DNA1000 kit. Sequencing was performed on the
Illumina Genome Analyzer II using a standard single
read 36-cycle sequencing protocol and Illumina’s sequenc-
ing reagents according to the manufacturer’s recommen-
dations. Each library was sequenced individually on a
single ﬂow cell lane, except for the +b-E2 replicate
1 (‘activated’-Myb B1), which was sequenced on two
lanes (B1T1 and B1T2, respectively). Sequencing yield of
 b-E2 isotype control antibody sample was signiﬁcantly
lower than other samples. Thus it was excluded in the
subsequent EdgeR analysis (see below).
ChIP-Seq data analyses
The data analysis methodology was summarized in
Supplementary Figure S7A. We performed base calling,
sequence tags quality assessment, and alignment of
sequence tags to the reference mouse genome (mm9,
UCSC assembly, July 2007) using Illumina Data
Analysis Pipeline software v.1.4. Only high quality
sequence tags with unique mapping positions to the
reference genome were used for identiﬁcation of MBRs
and further analyses.
To identify possible binding regions, we combined rep-
licate ‘activated’-Myb (0 h,+b-E2) and ‘inactivated’-Myb
(6 h,  b-E2) samples, respectively, and ran MACS
analysis (31) using the optimized parameters -bw110
-d55 -pval1e-3. This very conservative P-value cutoff gen-
erated 81 639 unique (MBRs). Of these, only 1417 have
adjusted P<10
 40 with the number of binding regions
Figure 1. Expression proﬁling analysis of Myb regulated genes.
(A) Schematic diagram of the experimental design. (B) The ER-Myb
fusion transcript is expressed at an almost identical level to endogenous
Myb mRNA in c-Kit
high bone marrow progenitors. Expression was
measured by qRT–PCR and normalized to Hprt. The level of the
ER-Myb fusion was set to 1. Data are presented as mean±SD.
(C) Hierarchical clustering of normalized expression levels of class A
Myb regulated genes, including 352 Myb-activated and 460 repressed
genes. The heat map of relative log2-transformed expression levels
during the b-E2 withdrawal and re-addition time course is shown;
each row represents a single gene. Simpliﬁed arrow diagrams of corres-
ponding kinetic proﬁles are shown next to each cluster tree. (D) The
majority of candidate Myb regulated genes were validated in both
ERMYB cells and Myb transduced primary bone marrow cells.
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 10 (Supplementary
Figure S7B). These regions form the basis of the replicate
design whereby the 36bp sequence tags were extended to
200bp to reﬂect the actual sequencing library size and the
total number of tag coverage in each region identiﬁed by
MACS calculated using R-code for each sample. The
restriction to regions with bi-modal binding peaks
excludes the ‘anomalous’ binding regions (32) that we
also observed in our data set.
Individual counts per region were utilized in differential
analysis of ‘activated’-Myb, ‘inactivated’- and isotype
control samples using the EdgeR package (33). Since at
the time of analysis the EdgeR program did not model
technical replicates (there were one technical replicate
and two biological replicates in the ‘activated’-Myb
class), we made the four comparisons comprised of
‘activated’-Myb (B1T1+B2) and ‘activated’-Myb
(B1T2+B2) sets against the ‘inactivated’-Myb (B1+B2)
set and the isotype control (B1) where B1 or B2 denotes
‘biological replicate’ 1 or 2 and T1 or T2 denotes ‘tech-
nical replicate’ 1 or 2. We required that binding regions
have P<10
 10 of at least two of these comparisons and a
positive fold change (signal of ‘activated’-Myb sample
greater than that of ‘inactivated’-Myb sample or isotype
control) to pass the P-value and fold change ﬁlter. This
cutoff identiﬁed all but 139 of the regions identiﬁed
with the MACs program with a P-value threshold
<10
 40. These additional 139 regions were included in
our subsequent analysis.
We then applied additional constraints in the form of
the minimum sequence tag number per region, in doing so
we did not apply a ‘ﬁxed’ tag count threshold but a
position dependent one as follows: for each binding
region we calculated the average background coverage
per base pair in the isotype control in the same genomic
regions ±2.5kb. This average excludes counts in previ-
ously deﬁned binding regions in that range. This average
coverage per base pair is normalized by the total number
of tags in the isotype control and then used to calculate the
expected number of ‘background’ counts in the corres-
ponding Myb-‘activated’ region. We represent the signal
above background in the ith Myb-‘activated’ region using
a z-score deﬁned as zi=(Ci–pi Li)/sqrt(pi Li(1 pi))
where Ci is the observed number of counts in the ith
Myb-‘activated’ region of length Li and pi is the back-
ground coverage per base pair multiplied by the total
number of reads [we assume background reads have
Poisson distribution: mean=pi Li; SD=sqrt(pi
Li (1 pi)]. As an example, the distribution of zi for
chromosome 2 is shown in Supplementary Figure S7C.
The regions above the determined threshold for zi are
shown in Supplementary Figure S7D. A ﬁxed threshold
for zi at the peak of the distribution (Supplementary
Figure S7C), is similar to an overall tag cutoff of 8.5
tags/region (denoted by the orange horizontal line in
Supplementary Figure S7D), but is biased against long
binding regions with few counts.
In total 11 429 candidate binding regions pass the
EdgeR P-value and tag number ﬁlter. These are enriched
for binding regions with small P-values in the MACs
analysis but also include a number of regions with large
MACs P>10
 4 (Supplementary Figure S7B). Almost all
of a selected set of these regions were subsequently
validated by independent ChIP-qPCR (Figure 4),
providing us with some evidence that the combined repli-
cate and pooled approach has provided additional MBRs
without dramatically increasing the false discovery rate.
We then performed de novo sequence motifs identiﬁca-
tion and enrichment analyses using the MEME algorithm
(34). Two-hundred bp sequences (100bp on either side of
peak summits) were used as MEME input. The following
parameters were applied to the input data sets: -text
-revcomp -dna -mod oops -nmotifs 4 -minw 6 -maxw 12
-maxsize 5000000. Sequence logos were generated using
WebLogo 2.8.2 (35).
We subsequently ﬁltered the 11429 candidate MBRs
for presence of Myb binding motif by scanning 160bp
sequences (80bp on either side of peak summits) of can-
didate MBRs with the identiﬁed position weight matrix
for Myb binding (Figure 2C) with a threshold of 0.8
determined empirically. The resultant list comprises 7646
high-conﬁdence MBRs (Supplementary Table S5). We
subsequently assigned each MBR to its nearest gene ac-
cording to its distance to transcription start site (TSS).
Upon closer examination of the 3783 regions which
passed all ﬁlters except the Myb binding consensus ﬁlter,
we found that many of these contain Myb binding
motif-like sequences, so at least some of them may be
true Myb occupied regions. Thus we have also provided
a list of these additional regions (Supplementary
Table S6).
To identify transcription factors that could potentially
bind to other enriched sequence motifs within MBRs, we
compared these motifs to known transcription factor
binding matrices in the Transfac database (v11.3) using
STAMP (36).
Gene set enrichment analysis
We ranked genes detectably expressed in ERMYB cells or
in MYB
KD THP-1 cells by the additive inverse of fold
change values (for ERMYB data, fold change values
from 0 to 24h after b-E2 withdrawal were used). Top
200 Myb activated or repressed genes in either data set
were determined based on their fold change values.
Curated gene sets were either extracted from the indicated
references or downloaded from MSig database (37). Gene
set enrichment analysis (GSEA) was performed using
GSEA v2.0 software with pre-ranked list and 1000 data
permutations.
Pathway analysis and network construction
We identiﬁed the enriched physiological development and
molecular function terms in direct Myb target genes were
identiﬁed using the core analysis tool of Ingenuity
Pathway Analysis program (IPA) program (http://www
.ingenuity.com/). We then extracted transcriptional
factors from direct Myb targets and constructed a tran-
scriptional regulatory network consisting of Myb and its
target transcription factors using IPA (Supplementary
Figure S6). The interconnections between the nodes were
visualized by adding direct interactions. Subsequently the
Nucleic Acids Research, 2011,Vol.39, No. 11 4667Figure 2. Global identiﬁcation of MBRs in vivo.( A) Both anti-ER antibody and anti-Myb sera worked in ChIP assays in ERMYB cells: the
ER-Myb fusion protein occupied a known Myb binding site in Mpo promoter (Mpo -0.32kb). B2m TSS region served as a negative control.
(B) Representation of ChIP-Seq sequencing reads (raw data) across loci of two established Myb targets—Mpo and Bcl2. (Arrows) ChIP-Seq
peak locations relative to TSS of the respective gene (kb). (C) Identiﬁed Myb motif shares the AACNG core binding consensus sequence with
the previously reported Myb binding consensus in Transfac database. (D) Distribution of MBRs relative to the nearest TSS (kb). Regions 50 to the
TSS are indicated as negative values on the x-axis. (E) Distribution of MBRs relative to Refseq gene features.
4668 Nucleic Acids Research, 2011,Vol.39, No. 11most interconnected hubs were extracted to reveal the core
regulatory network shown in Figure 7.
Runx1 was identiﬁed as a Myb bound gene having
multiple MBRs associated with (Supplementary
Table S5). One of these MBRs was conﬁrmed using inde-
pendent ChIP-qPCR in both ERMYB and HL-60 cells
(Figure 3). Runx1 was likely to be repressed by Myb
albeit with an atypical kinetic proﬁle of Myb repressed
genes in our ERMYB expression proﬁling (due to the rela-
tively small and insigniﬁcant fold changes from 0 to 6h
and from 6 to 24h after b-E2 withdrawal, even though
the change from 0 to 24h is signiﬁcant). Hence it was
initially classiﬁed as a class C (not Myb-regulated) gene
(Supplementary Table S2). Subsequently we validated
the repression of Runx1 by Myb using qPCR in both
ERMYB cells and Myb transduced bone marrow cells
(Supplementary Tables S3 and S4). Based on these
results, we conclude that Runx1 is a direct Myb repressed
target. Therefore it was included as a direct Myb target
gene in Supplementary Tables S7 and S8, and was also
Figure 3. Validation of ChIP-Seq ﬁndings. (A) All 23 high-conﬁdence MBRs were validated in ERMYB cells. Four of 5 MBRs (denoted by
) which
just failed EdgeR P-value ﬁlter were also validated. Four irrelevant regions were included as negative controls. (B) Twenty-ﬁve of 27 MBRs validated
using anti-ER antibody (A) were further validated using anti-Myb sera. Data are presented as mean±SD. Background binding level represents
(mean+1.64 SD) of a-ER or a-Myb signals of four irrelevant control regions. ‘Asterisk’ denotes signiﬁcant decreases in Myb occupancy upon b-E2
withdrawal (Student’s t-test, P<0.05). (C) Twenty of 21 conserved MBRs were further validated in HL-60 cells using pooled MYB antibodies.
Background binding level represents (mean+1.64 SD) of a-MYB signals of three control regions.
Nucleic Acids Research, 2011,Vol.39, No. 11 4669included in the pathway analysis and network construc-
tion using the IPA program.
RESULTS
Expression analysis of Myb regulated genes
We used the ERMYB cell line (21) as a model system to
identify genes regulated by Myb using whole genome
microarray expression proﬁling. ERMYB is a myeloid
progenitor cell line derived by transformation of primary
fetal liver cells by an activated form of Myb (CT3-Myb)
fused to the ligand binding domain of the estrogen
receptor a (ERa). This model system offers several advan-
tages for characterizing the Myb transcriptional program.
First, these cells strictly require activation of the Myb
fusion protein by b-estradiol (b-E2) to maintain a prolif-
erative progenitor-like phenotype and undergo monocytic
differentiation when Myb is inactivated by withdrawal of
b-E2. Thus this model is ideal for identifying those genes
accounting for Myb’s transforming and differentiation-
suppressing activities. Second, this model system
provided us with a unique opportunity to distinguish
between direct and indirect effects of Myb, by integrating
expression proﬁling and genome occupancy data (which
currently is technically very difﬁcult in other cell lines or
primary cells). Third, re-activation of Myb within 24h
after b-E2 withdrawal can fully reverse the differentiation
of these cells, allowing us to investigate the dynamic
pattern of target gene expression in response to Myb in-
activation and re-activation (depicted in Figure 1A). We
reasoned that this strategy is more likely to identify true
Myb target genes than conventional approaches in which
differential expression is examined only at the endpoint of
induction. Finally, the ER-Myb fusion transcript is ex-
pressed at levels very similar to physiological levels of en-
dogenous Myb mRNA in primary bone marrow c-Kit
high
progenitor cells (Figure 1B), while endogenous Myb
protein is undetectable in ERMYB cells (21). Findings
from this model system should thus enable us to more
accurately deﬁne Myb’s actions than would be the case
with a simple overexpression system.
We performed whole genome expression proﬁling with
cells from the b-E2 withdrawal and re-addition time course
(Figure 1A) and grouped genes according to their kinetic
proﬁles (Supplementary Table S2). We reasoned that
genuine Myb target genes (class A) should manifest
kinetic proﬁles consistent with Myb activity: Myb
activated genes should be down-regulated when Myb
activity is switched off and up-regulated when Myb is
turned on again, while Myb repressed genes should
show the opposite proﬁles (Figure 1C). The second group
of genes (class B) did not conform to class A proﬁles but
responded partially to inactivation and re-activation of
Myb (Supplementary Figure S1). That is, they showed at
least one signiﬁcant response to either b-E2 withdrawal or
re-addition. In fact some established Myb target genes,
such as Mpo (38) and Elane (39), were found within this
class (Supplementary Table S2). The third group (class C)
included genes with proﬁles incompatible with direct
regulation by Myb, genes with unperturbed expression
and genes not detectably expressed.
In total, we identiﬁed 2368 Myb regulated genes (2667
probe IDs) of classes A and B, of which 1171 genes were
activated and 1197 genes were repressed by Myb
(Supplementary Table S2). Of these we selected 89 candi-
dates and re-examined their expression using quantitative
PCR (qPCR) with TaqMan low density arrays (TLDAs,
see Supplementary Table S3). qPCR results for 75 genes
(84.3%) in ERMYB cells were consistent with the micro-
array results (Figure 1D and Supplementary Table S3).
We carried out further validation in mouse primary
bone marrow cells which were transduced with
retroviruses encoding either wild-type Myb (wt-Myb) or
an activated form, CT3-Myb, and then cultured in the
presence of granulocyte-macrophage colony stimulating
factor (GM-CSF) for 7 days. Under these conditions,
vector transduced control cells strongly down-regulated
Myb (Supplementary Table S4) and underwent myeloid
differentiation. In contrast, both wt-Myb and CT3-Myb
virus transduced (and transformed) cells overexpressed
Myb and did not differentiate (15). Note that Myb
overexpression was relatively modest in this system, with
wt- and CT3 forms being expressed at  3 and  5 times,
respectively, the level found in Kit
high progenitors (i.e. at
Day 0). We again measured expression of the 89 candidate
Myb regulated genes using TLDAs. The majority of can-
didate genes examined (60 genes; 67.4%) showed expres-
sion patterns consistent with Myb regulation in that they
maintained activation or repression in the presence of
ectopic wt-Myb or CT3-Myb expression (Figure 1D and
Supplementary Table S4). Notably, the impacts of
wt-Myb and CT3-Myb on their target genes largely
overlap. That is, 88.3% of the validated genes were con-
sistently regulated by both wt-Myb and CT3-Myb
(Supplementary Table S4). However, expression changes
caused by CT3-Myb were generally greater than those by
wt-Myb, especially of those commonly repressed genes (38
of 39; Supplementary Table S2).
Global analysis of MBRs in vivo
We next examined genome-wide Myb occupancy pattern
in ERMYB cells using ChIP-Seq. We ﬁrst tested the ChIP
performance of antibodies recognizing either the ER
moiety (ER-10 antibody) or the CT3-Myb portion
[anti-CT5 (29) and Thelma (30) sera] of the ER-Myb
fusion protein. We detected strong occupancy of Myb at
a known Myb binding site in Mpo proximal promoter
[ 0.32kb; (38)] using either anti-ER antibody or anti-
Myb sera (Figure 2A). Due to limited supply of the
anti-CT5 sera and lack of commercially available Myb
antibodies recognizing the CT3-Myb portion of the
ER-Myb fusion protein (most of these recognize
the C-terminus of wt-Myb protein which is absent in the
ER-Myb fusion protein), we carried out ChIP-Seq using
the ER antibody (see ‘Materials and Methods’ section for
more information).
Genome-wide maps of in vivo Myb chromatin occu-
pancy were generated using ChIP-Seq with two biological
replicate samples from ERMYB cells with activated and
4670 Nucleic Acids Research, 2011,Vol.39, No. 11inactivated Myb (i.e. 0 and 6h; Figure 1A). We ﬁrst
examined raw ChIP-Seq data across loci corresponding
to two known Myb target genes (Figure 2B), Mpo (38)
and Bcl2 (40,41). In addition to the previously reported
binding site within the proximal Mpo promoter ( 0.3kb
relative to the TSS), we identiﬁed two peaks further
upstream ( 3.5 and  4.2kb). These peaks were absent
or greatly diminished when Myb was inactivated by b-E2
withdrawal. Although it was suggested previously that
Myb activates Bcl2 transcription by binding to its
proximal promoter in T cells (40,41), we were unable to
detect any signiﬁcant Myb occupancy of the Bcl2
promoter. Instead, we found one intronic peak
(+93.9kb) and two downstream peaks (+196.5 and
+198.5kb, respectively). This indicates that Myb may
bind to different locations to regulate the same target in
different cell types. In fact we have detected Myb binding
to both the proximal promoter region and two conserved
downstream binding sites (+93.9 and+198.5kb) of Bcl2 in
human breast cancer cells (42).
We identiﬁed candidate MBRs using the MACS algo-
rithm (31), and removed those inconsistent between repli-
cate samples (Supplementary Figure S7A) using the
EdgeR package (33). These candidates were further
ﬁltered for sequence tag number and fold change
between samples with activated and inactivated Myb, re-
sulting in the identiﬁcation of 11 429 candidate MBRs (see
also ‘Materials and Methods’ section).
To determine the preferred sequences bound by Myb
in vivo, we interrogated the sequences of these candidate
MBRs for overrepresented DNA motifs using the MEME
program (34). Notably, we identiﬁed the Myb binding
motif itself to be the most prevalent sequence motif,
which shares the same AACNG core with the known
Myb binding consensus (Transfac V$MYB_Q6) but
differed at ﬂanking positions (Figure 2C). These Myb
binding sequences were centered on peak summits as
expected (Supplementary Figure S2A). We then applied
this consensus sequence ﬁlter to further reﬁne the candi-
date MBRs. The resultant set of 7646 high-conﬁdence
MBRs corresponds to 4892 unique genes (hereafter
deﬁned as Myb bound genes; Supplementary Table S5),
and includes many Myb target genes reported previously
in other systems (Supplementary Table S1).
The majority of identiﬁed MBRs is distal from the
nearest TSS although there is enrichment near TSS
(Figure 2D), with only 18% of MBRs occurred within
gene promoters [deﬁned here as ±2.5kb to the TSS;
(43)]. Further analysis of MBR distribution relative to
annotated Refseq gene features (Figure 2E) revealed that
occupancy was predominantly intergenic (46%) and
within introns (35%).
To validate our ChIP-Seq ﬁndings, we ﬁrst performed
qPCR on samples from an independent ChIP using ER
antibody with primers for 23 high-conﬁdence MBRs, rep-
resenting those associated with Myb activated, repressed
or other bound genes. As shown in Figure 3A, Myb
occupancy at all 23 MBRs was signiﬁcantly higher than
that of four irrelevant control regions, and decreased sig-
niﬁcantly upon Myb inactivation by b-E2 withdrawal.
Additionally, we selected ﬁve MBRs which had EdgeR
P-values just above the empirical cutoff (10
 10; see
‘Materials and Methods’ section) but had low MACS
P-values, of which, four were also validated (Figure 3A).
This suggests that while our list of identiﬁed MBRs is of
high-conﬁdence, there are probably additional MBRs that
remain to be validated.
We further validated these MBRs by ChIP-qPCR using
anti-Myb sera (anti-CT5 and Thelma sera). Twenty-ﬁve
of 27 MBRs validated in ChIP using ER antibody
(Figure 3A) were also validated in ChIP using anti-Myb
sera (Figure 3B), further conﬁrming that the MBRs we
identiﬁed in ChIP-Seq were indeed occupied by Myb
in vivo. The two MBRs that were validated using anti-
ER antibody but not validated using anti-Myb sera
(Gﬁ1  1.8kb and Sfpi1  0.13kb) were probably due to
the high background of the anti-Myb sera (Figure 3A and
B). In fact, both of these MBRs were validated in HL-60
cells (Figure 3C; see below).
To provide further conﬁdence, we carried out ChIP
using pooled MYB antibodies (Myb 1-1 antibody and
Thelma sera) in HL-60 cells, human leukemic
pro-myeloblasts that represent a similar stage to
ERMYB cells in myeloid development. We demonstrated
that endogenous MYB occupied 20 of 21 conserved
MBRs identiﬁed in mouse ChIP-Seq (Figure 3C), albeit
with signiﬁcantly lower signals than the ER-Myb fusion
protein which was probably due to the lower ChIP efﬁ-
ciency of the MYB antibodies used. These results conﬁrm
that our approach was highly effective in identifying bona
ﬁde Myb-occupied sites in vivo.
Identiﬁcation of direct Myb target genes
We next assessed whether the identiﬁed MBRs pinpoint
Myb regulated genes by integrating the expression
proﬁling data with the Myb chromatin occupancy data.
As illustrated in Figure 4A, of 4892 high-conﬁdence
Myb-bound genes, 793 are, as members of classes A or
B, transcriptionally regulated by Myb and thus are likely
to represent direct Myb target genes. Of those, 418 were
activated and 375 genes were repressed by Myb
(Supplementary Table S7). The fact that we identiﬁed
similar numbers of direct Myb activated and repressed
targets indicates that Myb can genuinely function as a
transcriptional repressor in addition to its established
role as a transactivator.
To cross validate our ﬁndings, we examined a published
set of differentially expressed genes upon siRNA mediated
MYB knockdown (MYB
KD) in human THP-1 leukemia
cells (19). This revealed a large overlap between this set
and our sets of Myb bound or Myb regulated genes
(Figure 4B and Supplementary Table S8): 1063 genes dif-
ferentially expressed upon MYB
KD were bound by Myb in
ERMYB cells; and 462 genes differentially expressed in
MYB
KD THP-1 cells were also regulated by Myb in
ERMYB cells. Moreover, GSEA (37) showed that the
top 200 Myb-activated or -repressed genes (ranked by
fold change) identiﬁed in ERMYB cells were signiﬁcantly
enriched in the THP-1 MYB
KD set, and vice versa
(Supplementary Table S9).
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mediator of Hoxa9 and Meis1signaling, and is essential
for transformation by these two oncogenes (13). We
examined the up- or down-regulated gene sets by
Hoxa9/Meis1, reasoning that at least part of these gene
signatures should be imposed by Myb, if Myb is a essen-
tial downstream target of this signaling pathway. Using
GSEA, we found this is indeed the case: the two gene sets
were very signiﬁcantly overrepresented in either Myb
activated genes or repressed genes identiﬁed in ERMYB
cells (Supplementary Table S9), thereby validating our set
of Myb regulated genes.
Characterization of MBRs associated with direct Myb
target genes
The majority of Myb bound genes (80.7%; Figure 4A)
were not clearly regulated by Myb. In order to gain
insights into why some Myb bound genes were regulated
by Myb whereas others not, we compared the average
number of associated MBRs per gene for Myb bound
genes in different microarray classes (Figure 5A). Direct
Myb targets (bound genes in classes A and B) appeared to
have signiﬁcantly more MBRs than those bound but not
Myb-regulated or not expressed (class C), with the highest
Figure 5. MBRs were enriched near Myb target genes. (A) Direct Myb targets (classes A and B) generally have signiﬁcantly more MBRs than those
Myb bound but not regulated or not expressed genes (class C). *P<0.05 (Wilcoxon rank sum test). (B) MBRs are enriched in the proximity of
TSS of Myb activated genes (classes A and B). Myb repressed genes appeared to have more MBRs at locations relatively distal to TSS. Average
numbers of MBR per gene of each microarray class were plotted against their distances relative to the nearest TSS in 1kb bins up to 20kb away
from TSS.
Figure 4. Integration of expression proﬁling and genome occupancy
data. (A) Direct Myb target genes were deﬁned as genes bound and
regulated by Myb, including 418 Myb-activated and 375 repressed
targets. (B) Signiﬁcant overlap between Myb bound genes, Myb
regulated genes in ERMYB cells and differentially expressed genes in
MYB
KD THP-1 cells.
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in class A. Consistently, distribution analysis of MBRs
relative to genes in each microarray class revealed higher
enrichment of MBRs near TSS of Myb activated genes
(classes A and B) compared with genes not regulated or
expressed (class C) whereas Myb repressed genes (classes
A and B) appear to have more MBRs at locations further
to TSS (Figure 5B).
To identify other transcription factors that might con-
tribute to Myb regulation of its target genes, we analyzed
overrepresented sequence motifs within MBRs (100bp
window from either side of peak summit) associated
with Myb activated, repressed and not Myb-regulated/
not expressed genes. We then compared these motifs to
the Transfac database to identify putative corresponding
factors (Supplementary Figure S2C). We found that the
binding motifs for Runx1 and for Ets family members,
such as Ets1/2, Sfpi1, Evx1/2 and Elf1, were enriched in
all three categories. These results are consistent with
previous reports that Myb interacts with these factors to
regulate target gene expression (39,44–46). Interestingly,
motifs resembling a half-MARE (Maf response element)
for large Maf proteins were enriched in Myb repressed or
not Myb-regulated/not expressed genes. Maf has been
shown to interact with Myb and repress Myb transacti-
vation of certain targets in both myeloid and T lineages
(47–49). Reciprocally, Myb can repress Mafb transactiva-
tion in a SUMO-dependant manner (50). Taken together,
these results suggest that Maf/Mafb may be cofactors
important for Myb repression of some genes.
p300 occupies MBRs in vivo, and is required for
repression and activation of Myb targets
Cbp/p300 is a known co-activator of Myb (51,52). Mice
carrying point mutations of p300 which disrupt the Myb
interaction site (53,54) partially resemble the phenotypes
of Myb hypomorphic mice (55,56). Furthermore, we have
shown that interaction with Cbp/p300 is essential for
transactivation and transformation by Myb (15). Hence
we examined our set of validated MBRs for Cbp/p300
occupancy in ERMYB cells. We detected p300 occupancy
at 25 of 27 MBRs, regardless of whether they were
associated with Myb activated or repressed genes
(Figure 6A). Moreover, the p300 occupancy followed the
changes in Myb occupancy: decreased occupancy of both
Myb and p300 was evident when b-E2 was withdrawn
from the cells. In contrast, Cbp occupancy was only
detected at few MBRs, and moreover, did not parallel
Myb occupancy (Supplementary Figure S3).
To further elucidate the role of p300 interaction in tran-
scriptional regulation by Myb, we transduced mouse
primary bone marrow cells with retroviruses encoding
either CT3-Myb or L302A.CT3-Myb (15) and cultured
them in GM-CSF for 7 days as in the previous validation
experiment. The latter Myb mutant carries the L302A
point mutation which completely abolishes the
Myb-p300 interaction (51). We measured and compared
the expression of 53 direct Myb target genes (validated
previously; Supplementary Table S4) in cells expressing
these two forms of Myb. Consistent with the established
role of p300 as a co-activator for Myb (51,52), we found
(Figure 6B) that expression of Myb activated genes was
signiﬁcantly decreased in cells expressing L302A.CT3-
Myb compared to CT3-Myb (15 of 19 genes, 78.9%).
Interestingly, the expression of Myb repressed genes was
signiﬁcantly increased in cells expressing L302A.CT3-Myb
(29 of 34 genes, 85.3%), suggesting that transcriptional
repression by Myb was relieved by abolishing p300 inter-
action. Taken together, these data suggest that p300 has a
hitherto-unappreciated role in mediating transcriptional
repression by Myb, in addition to its established role as
coactivator.
We were also interested in whether we could detect
p300-mediated activation and repression of Myb targets
in primary myeloid progenitor cells expressing only en-
dogenous Myb. To this end we puriﬁed GMPs (23) from
wild-type mice and from the ‘booreana’ mutant strain.
The latter carries a mutation (E308G) in Myb which
greatly reduces or abolishes its association with p300
(24). qPCR analysis of a set of 11 Myb-activated and 11
Myb-repressed genes (Supplementary Figure S4) showed
that expression of all of the Myb-activated genes was sig-
niﬁcantly decreased in the ‘booreana’ GMPs, reinforcing
p3000s role as a physiological coactivator of wt-Myb.
Expression of six of the Myb-repressed genes identiﬁed
above was signiﬁcantly increased in the ‘booreana’
GMPs, indicative of reduced repression, as anticipated.
However, the magnitude of the increase was substantially
less than that seen in the ectopic expression study of
Figure 6B, and moreover, no signiﬁcant increase was
seen in the levels of the other ﬁve genes. The implications
of these data are discussed below.
Myb modulation of histone modiﬁcation
p300 has histone acetyltransferase activity that contributes
to its function as a transcriptional coactivator (57). We
therefore examined acetyl-histone 3 (H3ac) levels at our
set of validated MBRs. Most of these regions showed sig-
niﬁcant H3ac levels, consistent with the fact that the cor-
responding genes were detectably expressed. However,
changes in H3ac upon dissociation of Myb and p300
were detected at only 7 of 27 MBRs and were not consist-
ent with changes in p300 occupancy in most cases
(Supplementary Figure S5A). Moreover, changes in
H3ac levels generally correlated poorly with the expres-
sion changes of corresponding genes.
We next examined the set of validated MBRs for other
epigenetic markers, including two activating histone
marks—trimethylated histone H3 lysine 4 (H3K4me3)
and the monomethylated form (H3K4me1) (58), and two
repressive marks—trimethylated form of histone H3 lysine
9 (H3K9me3) and lysine 27 (H3K27me3) (59). Most
MBRs examined are ‘bivalent’ as they had high levels of
both activating and repressive markers (Supplementary
Figure S5B–E).
Upon dissociation of Myb, we detected signiﬁcantly
increased levels of the heterochromatin marker
H3K9me3 at most MBRs (23 of 27, Supplementary
Figure S5D), regardless of whether they are associated
with Myb-activated or -repressed genes. This suggests
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matin structure at its target loci. We also detected a sig-
niﬁcant increase in another repressive mark H3K27me3 at
6 of 14 MBRs associated with Myb activated genes
(Supplementary Figure S5E). This implies that, at least
at a subset of Myb activated genes, Myb may help to
inhibit the recruitment of the polycomb repressor
complex PRC2 [responsible for H3K27me3; (59)],
thereby activating target gene transcription. The levels of
the activating promoter mark H3K4me3 upon Myb dis-
sociation were increased at most of MBRs examined
(Supplementary Figure S5B), albeit with relatively small
fold changes. The levels of enhancer marker H3K4me1
were largely unchanged (Supplementary Figure S5C).
These observations raise the possibility that Myb may
form similar complexes at both activated and repressed
targets which result similar changes in histone modiﬁca-
tions, and that the actual effects of these epigenetic
changes may depend largely on local context, previous
epigenetic memory and/or other unexamined histone
modiﬁcations. It may also be that the major, immediate
effects of Myb on target gene transcription may be
mediated by other mechanisms or activities such as
direct effects on the core transcriptional machinery.
Gene signatures for cancer, stem cells and myeloid
development are overrepresented in the Myb
transcriptional program
As discussed above activation of Myb is widely associated
with leukemia and it is expressed in most leukemias even
in the absence of genetic alteration. In agreement with
this, GSEA (Table 1) demonstrated that the MLL LSC
gene signature was highly enriched in Myb-regulated
genes (in the appropriate directions). Gene sets comprising
commonly up-regulated genes in cancer compared with
normal tissue, or undifferentiated cancer compared with
well differentiated cancer, were also signiﬁcantly enriched
for Myb-regulated genes. Consistent with an important
MYB contribution to human acute myeloid leukemia
(AML), gene sets associated with several subtypes of
Figure 6. p300 was required for both activation and repression by Myb. (A) p300 occupancy was detected at 25 of 27 MBRs and the occupancy
generally decreased when Myb was inactivated by b-E2 withdrawal. Data are presented as mean±SD. IgG background represents the (mean+1.64
SD) of IgG signals across all regions. ‘Asterisk’ denotes signiﬁcant decrease in Myb occupancy upon b-E2 withdrawal (Student’s t-test, P<0.05).
(B) L302A.CT3-Myb did not maintain the repression or activation of direct Myb target genes by CT3-Myb. Expression of 53 direct Myb target genes
was shown for L302A.CT3-Myb transduced bone marrow cells (y-axis, log2 scale) relative to CT3-Myb transduced cells (set to 1). ‘Asterisk’ denotes
signiﬁcant difference between the two samples (Student’s t-test, P<0.05).
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and other CBF subtypes), were all (negatively) enriched in
Myb-repressed genes, whereas a gene set down-regulated
in nucleophosmin-mutated (NPMc
+) AML was positively
enriched. This suggests that Myb repressed genes may be
characteristic of some subtypes of AML (and is consistent
with the importance of Myb-mediated repression in
leukemia), while in NPMc
+ AML, Myb activity may be
reduced, resulting in down-regulation of its activated
target genes.
Myb is essential for maintaining the adult HSC pool (3).
Consistently, gene sets associated with HSCs and pro-
genitors were positively enriched, whereas gene sets up-
regulated in mature blood cells were negatively enriched
in the Myb transcriptional program. Moreover, consistent
with the essential role Myb plays in myeloid development
and myeloid transformation (1), gene sets associated with
myeloid proliferation and self-renewal were signiﬁcantly
enriched in Myb activated genes while gene sets for
myeloid differentiation were overrepresented in Myb
repressed genes.
Functional analysis of identiﬁed direct Myb targets
using the IPA revealed signiﬁcant enrichment of genes
associated with terms such as ‘hematological system de-
velopment and function’ and hematopoiesis (Table 2).
Other signiﬁcantly overrepresented molecular function
terms (Table 2) included cell death, cell growth and pro-
liferation, cell cycle and cell signaling. Collectively, these
results re-emphasized the importance of Myb in hemato-
poiesis and pinpointed the key cellular pathways regulated
by Myb.
Myb controls a core transcriptional regulatory network
We identiﬁed 75 transcription factors as direct Myb
targets. We reasoned that such factors are likely to be
critical components of the Myb transcriptional program,
since in principle they can both crosstalk with each other
and regulate other cascades of genes that ultimately deﬁne
cellular phenotypes.
We therefore constructed a Myb-centric regulatory
network comprising Myb and its target transcriptional
factors with inferred regulatory interactions among
these factors from IPA (Supplementary Figure S6). The
most interconnected hubs were then extracted to con-
struct a core regulatory network (illustrated in Figure 7).
Interestingly, 8 of the 10 transcriptional hubs were
repressed by Myb while only 2 were activated. Many of
the repressed hubs are key positive regulators of myeloid
differentiation, such as Runx1, Sfpi1, Junb and Cebpb (60).
The activated hubs include Myc, a well established
oncogene and pluripotency factor (61) and Gﬁ1, which is
essential for HSC maintenance and neutrophil differenti-
ation (62,63). As discussed below, this transcriptional
regulatory network is likely to collectively account for
several of Myb’s key activities, such as promoting self-
renewal and suppressing differentiation.
DISCUSSION
The Myb transcriptional program and Myb function
In this study, we describe the transcriptional program
controlled by Myb in a myeloid progenitor-like cell line
Table 1. Gene signatures for cancer, stem cells and myeloid
development are overrepresented in the Myb transcriptional program
Gene set name NES FDR
Cancer gene sets
Up-regulated gene set in MLL LSC (20) 2.61 0
Down-regulated gene set in MLL LSC  2.80 0
ALCALAY_AML_NPMC_DN (73) 1.68 0.01
ROSS_CBF_MYH (74)  2.00 0.00
ROSS_AML1_ETO  1.58 0.04
ROSS_MLL_FUSION  1.55 0.05
ROSS_CBF  1.46 0.09
CANCER_UNDIFFERENTIATED_
META_UP (75)
2.16 0
CANCER_NEOPLASTIC_META_UP 1.94 0.00
Stem cell gene sets
HSC_EARLYPROGENITORS_FETAL (76) 2.07 0
HSC_EARLYPROGENITORS_ADULT 2.06 0
HSC_INTERMEDIATEPROGENITORS_
FETAL
1.85 0.00
HSC_INTERMEDIATEPROGENITORS_
ADULT
1.82 0.00
HSC_MATURE_ADULT  1.96 0.00
HSC_MATURE_FETAL  1.42 0.11
Myeloid development gene sets
BROWN_MYELOID_PROLIF_AND_
SELF_RENEWAL (77)
2.48 0
BROWN_GRAN_MONO_DIFFERENTIATION  2.84 0
MYELOID_CELL_DIFFERENTIATION (78)  1.83 0.01
LIAN_MYELOID_DIFF_RECEPTORS (79)  1.79 0.01
NES, normalized enrichment score; FDR, false discovery rate.
Table 2. Signiﬁcantly enriched pathway terms in direct Myb target
genes
Name P-value No. of
genes
Physiological system development and function
Hematological system development
and function
1.47E-11–4.46E-03 133
Hematopoiesis 3.51E-10–4.05E-03 85
Tissue morphology 2.71E-08–4.19E-03 82
Cell-mediated immune response 5.94E-08–2.99E-03 54
Skeletal and muscular system
development and function
2.81E-07–2.89E-03 22
Organismal survival 1.06E-06–1.11E-06 78
Tissue development 4.47E-06–4.24E-03 80
Immune cell trafﬁcking 1.35E-05–4.24E-03 58
Nervous system development
and function
5.23E-05–2.61E-03 35
Humoral immune response 8.54E-05–4.46E-03 36
Molecular and cellular functions
Cell death 1.25E-16–4.46E-03 230
Cellular growth and proliferation 3.74E-11–4.05E-03 231
Cellular development 8.90E-10–4.05E-03 182
Cellular function and maintenance 2.99E-08–4.46E-03 73
Cell cycle 4.47E-07–2.61E-03 101
Cellular movement 5.75E-07–3.07E-03 117
Cellular morphology 7.61E-07–4.18E-03 102
Cell-to-cell signaling and interaction 4.47E-06–4.11E-03 133
Cell signaling 1.43E-05–4.16E-03 58
Carbohydrate metabolism 5.62E-05–2.61E-03 10
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Integration of genome-wide chromatin occupancy data
and a comprehensive data set of Myb induced gene ex-
pression changes allowed us to identify direct Myb targets
by correlating in vivo occupancy and transcriptional
activity. A major ﬁnding reported here is the opposing
regulatory effect of Myb on the transcription of different
targets. This is reminiscent of the recent ﬁnding that
Drosophila Myb functions as both transcriptional activa-
tor and repressor in a promoter-dependent manner (64).
Consistent with its established role as a transcriptional
activator, we found Myb bound and activated 418 genes
(Figure 4A and Supplementary Table S7), thus extending
the network of genes that Myb directly activates.
Consistent with our ﬁndings, two recent studies (19,65)
showed that many genes were up-regulated upon
knockdown of MYB. However, this was attributed to
indirect mechanisms, i.e. Myb activated other repressors
to repress these genes. In direct contrast, we demonstrate,
for the ﬁrst time, that Myb directly repressed approxi-
mately half of its target genes (375 genes; Figure 4A and
Supplementary Table S7), indicating that transcriptional
repression is also a fundamental and major activity of
Myb.
Knockdown of MYB induced a differentiation-like
phenotype in THP-1 cells (19), as does inactivation of
Myb in ERMYB cells (21). In contrast, overexpression
of MEnT, a dominant negative construct which effectively
inhibits Myb transactivation (41), did not induce differen-
tiation of HL-60 cells (48). These ﬁndings pointed to the
fact that simple inhibition of transactivation by Myb is
not sufﬁcient to suppress differentiation. This is consistent
with our ﬁndings that Myb directly represses several key
positive transcriptional regulators of hematopoietic differ-
entiation, including Runx1, Sfpi1, Cebpb and Junb.
Together these observations support the notion that
repression by Myb is essential for its differentiation-
suppressing and transforming activities, and conversely,
that de-repression of certain Myb targets, such as the tran-
scription factors mentioned above, might be essential to
allow proper differentiation. This notion is embodied in
the core regulatory network in Figure 7.
It is however certain that other transcription factors
(such as Cited2), and genes other than those encoding
transcription factors also contribute to transformation
and suppression of differentiation by Myb. As shown in
Table 2, Myb regulated genes involved in several
pathways important for transformation, proliferation
and differentiation, including cell survival (such as Bcl2
and Ciapin1), cellular growth and proliferation (such as
Mapk3 and Tcf7l2) and cell signaling (such as Csf1 and
Gnai2).
A complex relationship between Myb repression, p300
and chromatin modiﬁcation
Transactivation by Myb has been relatively well character-
ized. It requires the transactivation domain (66) and inter-
action with the coactivator Cbp/p300 (51,52). However, it
is far less clear how Myb represses its targets, although
several models have been proposed. One model (67)
suggests that subtle differences in ﬂanking sequences of
Myb binding sites could potentially lead to conform-
ational changes in Myb upon binding to DNA and sub-
sequent recruitment of corepressors [several of which are
known to associate with Myb; (68)] instead of coactiva-
tors. However, we found that the consensus sequences
immediately ﬂanking the core ‘AACNG’ were almost
identical between genes directly activated by Myb and
those that were not Myb-regulated, with only a very
slight difference between direct Myb activated and
repressed genes (Supplementary Figure S2B). These obser-
vations do not favor the above-mentioned model.
Myb-mediated repression may also involve competition
with other positive transcription regulators as in the case
of ERBB2 promoter, where Myb competes with TBP (69).
Alternatively, Myb may require cell type- or developmen-
tal stage-speciﬁc factors to function as a repressor. For
example, repression of the Csf1r promoter by Myb
occurs in macrophages but not in ﬁbroblasts (45). This
is consistent with our ﬁndings that motifs for many hem-
atopoietic speciﬁc factors, such as Runx1, Ets factors and
Maf/Mafb are found adjacent to Myb binding motifs
(Supplementary Figure S2C). However, several of these
are common to Myb activated and repressed genes, so
cooperation with adjacently-bound factors is unlikely to
explain repression in many cases.
We propose another possible mechanism here based on
the fact that p300 was required for repression by Myb.
This is entirely consistent with our previous ﬁnding that
Cbp/p300 interaction is required for transformation by
Myb (15), and the notion discussed above that repression
by Myb is essential for transformation. Taken together,
this would suggest the seemingly paradoxical notion that
the coactivator p300 plays an essential role in repression by
Myb. Although rarely, p300 might contribute directly to
transcriptional repression (70). However, we suggest that
the Myb-p300 complex could suppress some Myb targets
by activating transcription of repressive non-coding
Figure 7. Myb controls a core transcriptional regulatory network.
Transcriptional factors directly targeted by Myb were used to construct
a network using IPA. The most interconnected factors were subsequently
extracted to construct a core regulatory network. Ellipses with gray
background represent Myb activated transcription factors, whereas
open ellipses with white background represent ones repressed by Myb.
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important feature of the eukaryotic transcriptome (71),
and include microRNAs, antisense transcripts and long
intergenic non-coding RNAs, all of which have known
or potential suppressive effects on gene expression. At
least for some repressed targets, Myb may employ the
same molecular mechanism—association with the p300
coactivator—for activation and repression; however in
the latter case Myb may repress these targets via activating
the transcription of interfering, gene-speciﬁc suppressive
ncRNAs. Indeed, we found that Myb binds to a number
of genes encoding microRNAs (Supplementary Table S5),
among which, the binding of Myb to two genes encoding
hematopoietic speciﬁc Mir181a-1 and Mir142 respectively
(72) have been validated in both ERMYB and HL-60 cells
(Figure 3 and Zhao,L. and Gonda,T.J. unpublished data).
This hypothesis is supported by our and other results.
First, p300, a well established transcriptional coactivator,
appears to co-occupy MBRs of both activated and re-
pressed genes with Myb (Figure 6A). Second, Myb dis-
sociation caused similar changes in H3K9me3 (and
H3K4me3) with both activated and repressed genes
(Supplementary Figure S5B and D). This argues in favor
of the idea that Myb recruits the same set of proteins to
its target genes regardless of whether they are to be
activated or repressed. Third, the distribution patterns of
MBRs near activated or repressed Myb targets show an
apparent difference (Figure 5B): generally, activated genes
have signiﬁcantly higher enrichment of MBRs in the prox-
imity of TSS whereas repressed genes tend to have more
MBRs at locations relatively distal to TSS. These distal
sites may be potential promoters that are activated upon
Myb binding and initiate transcription of the suppressive
ncRNAs.
We also found that in primary GMPs, p300-dependent
repression of those genes identiﬁed as repressed by
activated or ectopically-expressed Myb was less apparent.
This is consistent with the notion that transcriptional
repression of critical targets is a key activity of Myb in a
transforming/leukemic context, which as we discuss is
marked by suppression of differentiation. This is also in
line with our ﬁndings that gene signatures of several AML
subtypes are enriched in Myb repressed genes (Table 1).
One might expect less suppression of differentiation by
Myb in normal progenitors as these cells do in fact
differentiate.
To summarize, our data provide a genome-wide
analysis of Myb chromatin occupancy and target gene
expression. We demonstrated for the ﬁrst time that, in
addition to its established role as a transactivator, Myb
directly repressed a substantial number of genes including
key regulators of myeloid differentiation. This may shed
some light on the mechanisms of how Myb, and possibly
other oncogenes, transform hematopoietic cells and cause
malignances. We also provide evidence that the inter-
action with p300 is required for both transcriptional acti-
vation and repression by Myb, and suggest that the latter
may quantitatively distinguish Myb activity in trans-
formed versus normal contexts. Finally, this data set
should provide a valuable resource for further study of
the transcriptional regulation of hematopoietic develop-
ment and leukemic transformation.
ACCESSION NUMBERS
The ChIP-Seq and expression proﬁling data have been
deposited in the Gene Expression Omnibus (GEO)
database under accession numbers GSE22095 and
GSE22486, respectively.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Drs Michael Tallack and Andrew Perkins
(Institute for Molecular Bioscience, University of
Queensland, Australia) for advice about ChIP assays, Dr
Shunsuke Ishii (RIKEN, Tsukuba, Japan) for the CT5
Myb antibody and Dr Michael Rist (University of
Queensland Diamantina Institute) for assistance with
cell sorting.
FUNDING
National Health and Medical Research Council of
Australia (grant 569639 to T.J.G.); Australian Cancer
Research Foundation, Infrastructure grant; Leukemia
Foundation (Australia), PhD scholarship (to D.R.P.).
Funding for open access charge: Diamantina Institute
central funds.
Conﬂict of interest statement. None declared.
REFERENCES
1. Ramsay,R.G. and Gonda,T.J. (2008) MYB function in normal
and cancer cells. Nat. Rev. Cancer, 8, 523–534.
2. Mucenski,M.L., McLain,K., Kier,A.B., Swerdlow,S.H.,
Schreiner,C.M., Miller,T.A., Pietryga,D.W., Scott,W.J. and
Potter,S.S. (1991) A functional c-myb gene is required for normal
murine fetal hepatic hematopoiesis. Cell, 65, 677–689.
3. Lieu,Y.K. and Reddy,E.P. (2009) Conditional c-myb knockout
in adult hematopoietic stem cells leads to loss of self-renewal
due to impaired proliferation and accelerated differentiation.
Proc. Natl Acad. Sci. USA, 106, 21689–21694.
4. Wolff,L., Koller,R., Bies,J., Nazarov,V., Hoffman,B.,
Amanullah,A., Krall,M. and Mock,B. (1996) Retroviral
insertional mutagenesis in murine promonocytic leukemias: c-myb
and Mml1. Curr. Top. Microbiol. Immunol., 211, 191–199.
5. Lipsick,J.S. and Wang,D.M. (1999) Transformation by v-Myb.
Oncogene, 18, 3047–3055.
6. Lahortiga,I., De Keersmaecker,K., Van Vlierberghe,P., Graux,C.,
Cauwelier,B., Lambert,F., Mentens,N., Beverloo,H.B., Pieters,R.,
Speleman,F. et al. (2007) Duplication of the MYB oncogene in T
cell acute lymphoblastic leukemia. Nat. Genet., 39, 593–595.
7. Murati,A., Gervais,C., Carbuccia,N., Finetti,P., Cervera,N.,
Adelaide,J., Struski,S., Lippert,E., Mugneret,F., Tigaud,I. et al.
(2009) Genome proﬁling of acute myelomonocytic leukemia:
alteration of the MYB locus in MYST3-linked cases. Leukemia,
23, 85–94.
8. Clappier,E., Cuccuini,W., Kalota,A., Crinquette,A., Cayuela,J.-M.,
Dik,W.A., Langerak,A.W., Montpellier,B., Nadel,B., Walrafen,P.
et al. (2007) The C-MYB locus is involved in chromosomal
Nucleic Acids Research, 2011,Vol.39, No. 11 4677translocation and genomic duplications in human T-cell acute
leukemia (T-ALL), the translocation deﬁning a new T-ALL subtype
in very young children. Blood, 110, 1251–1261.
9. O’Neil,J., Tchinda,J., Gutierrez,A., Moreau,L., Maser,R.S.,
Wong,K.K., Li,W., McKenna,K., Liu,X.S., Feng,B. et al. (2007)
Alu elements mediate MYB gene tandem duplication in human
T-ALL. J. Exp. Med., 204, 3059–3066.
10. Castaneda,V.L., Parmley,R.T., Saldivar,V.A. and Cheah,M.S.
(1991) Childhood undifferentiated leukemia with early erythroid
markers and c-myb duplication. Leukemia, 5, 142–149.
11. Gorello,P., La Starza,R., Varasano,E., Chiaretti,S., Elia,L.,
Pierini,V., Barba,G., Brandimarte,L., Crescenzi,B., Vitale,A. et al.
(2010) Combined interphase ﬂuorescence in situ hybridization
elucidates the genetic heterogeneity of T-cell acute lymphoblastic
leukemia in adults. Haematologica, 95, 79–86.
12. Tomita,A., Watanabe,T., Kosugi,H., Ohashi,H., Uchida,T.,
Kinoshita,T., Mizutani,S., Hotta,T., Murate,T., Seto,M. et al.
(1998) Truncated c-Myb expression in the human leukemia cell
line TK-6. Leukemia, 12, 1422–1429.
13. Hess,J.L., Bittner,C.B., Zeisig,D.T., Bach,C., Fuchs,U.,
Borkhardt,A., Frampton,J. and Slany,R.K. (2006) c-Myb is an
essential downstream target for homeobox-mediated
transformation of hematopoietic cells. Blood, 108, 297–304.
14. Lidonnici,M.R., Corradini,F., Waldron,T., Bender,T.P. and
Calabretta,B. (2008) Requirement of c-Myb for p210BCR/
ABL-dependent transformation of hematopoietic progenitors and
leukemogenesis. Blood, 111, 4771–4779.
15. Pattabiraman,D.R., Sun,J., Dowhan,D.H., Ishii,S. and Gonda,T.J.
(2009) Mutations in multiple domains of c-Myb disrupt
interaction with CBP/p300 and abrogate myeloid transforming
ability. Mol. Cancer. Res., 7, 1477–1486.
16. Patel,G., Kreider,B., Rovera,G. and Reddy,E.P. (1993) v-myb
blocks granulocyte colony-stimulating factor-induced myeloid cell
differentiation but not proliferation. Mol. Cell. Biol., 13,
2269–2276.
17. Clarke,M.F., Kukowska-Latallo,J.F., Westin,E., Smith,M. and
Prochownik,E.V. (1988) Constitutive expression of a c-myb
cDNA blocks Friend murine erythroleukemia cell differentiation.
Mol. Cell. Biol., 8, 884–892.
18. Gonda,T.J., Buckmaster,C. and Ramsay,R.G. (1989) Activation
of c-myb by carboxy-terminal truncation: relationship to
transformation of murine haemopoietic cells in vitro. EMBO J.,
8, 1777–1783.
19. The FANTOM Consortium and the Riken Omics Science Center.
(2009) The transcriptional network that controls growth arrest
and differentiation in a human myeloid leukemia cell line. Nat.
Genet., 41, 553–562.
20. Somervaille,T.C.P., Matheny,C.J., Spencer,G.J., Iwasaki,M.,
Rinn,J.L., Witten,D.M., Chang,H.Y., Shurtleff,S.A.,
Downing,J.R. and Cleary,M.L. (2009) Hierarchical maintenance
of MLL myeloid leukemia stem cells employs a transcriptional
program shared with embryonic rather than adult stem cells.
Cell Stem Cell, 4, 129–140.
21. Hogg,A., Schirm,S., Nakagoshi,H., Bartley,P., Ishii,S.,
Bishop,J.M. and Gonda,T.J. (1997) Inactivation of a c-Myb/
estrogen receptor fusion protein in transformed primary cells
leads to granulocyte/macrophage differentiation and down
regulation of c-kit but not c-myc or cdc2. Oncogene, 15,
2885–2898.
22. Zhao,L., Neumann,B., Murphy,K., Silke,J. and Gonda,T.J. (2008)
Lack of reproducible growth inhibition by Schlafen1 and
Schlafen2 in vitro. Blood Cells Mol. Dis., 41, 188–193.
23. Akashi,K., Traver,D., Miyamoto,T. and Weissman,I.L. (2000) A
clonogenic common myeloid progenitor that gives rise to all
myeloid lineages. Nature, 404, 193–197.
24. Papathanasiou,P., Tunningley,R., Pattabiraman,D.R., Ye,P.,
Gonda,T.J., Whittle,B., Hamilton,A.E., Cridland,S.O., Lourie,R.
and Perkins,A.C. (2010) A recessive screen for genes regulating
hematopoietic stem cells. Blood, 116, 5849–5858.
25. Du,P., Kibbe,W.A. and Lin,S.M. (2008) lumi: a pipeline for
processing Illumina microarray. Bioinformatics, 24, 1547–1548.
26. Smyth,G.K. (2004) Linear models and empirical bayes methods
for assessing differential expression in microarray experiments.
Stat. Appl. Genet. Mol. Biol., 3, Article3.
27. Eisen,M.B., Spellman,P.T., Brown,P.O. and Botstein,D. (1998)
Cluster analysis and display of genome-wide expression patterns.
Proc. Natl Acad. Sci. USA, 95, 14863–14868.
28. Hodge,D., Coghill,E., Keys,J., Maguire,T., Hartmann,B.,
McDowall,A., Weiss,M., Grimmond,S. and Perkins,A. (2006) A
global role for EKLF in deﬁnitive and primitive erythropoiesis.
Blood, 107, 3359–3370.
29. Kanei-Ishii,C., Nomura,T., Tanikawa,J., Ichikawa-Iwata,E. and
Ishii,S. (2004) Differential Sensitivity of v-Myb and c-Myb to
Wnt-1-induced Protein Degradation. J. Biol. Chem., 279,
44582–44589.
30. Ramsay,R.G., Ciznadija,D., Mantamadiotis,T., Anderson,R. and
Pearson,R. (2005) Expression of stress response protein glucose
regulated protein-78 mediated by c-Myb. Int. J. Biochem. Cell
Biol., 37, 1254–1268.
31. Zhang,Y., Liu,T., Meyer,C., Eeckhoute,J., Johnson,D.,
Bernstein,B., Nussbaum,C., Myers,R., Brown,M., Li,W. et al.
(2008) Model-based Analysis of ChIP-Seq (MACS). Genome Biol.,
9, R137.
32. Pepke,S., Wold,B. and Mortazavi,A. (2009) Computation for
ChIP-seq and RNA-seq studies. Nat. Methods, 6, S22–S32.
33. Robinson,M.D., McCarthy,D.J. and Smyth,G.K. (2010) edgeR: a
Bioconductor package for differential expression analysis of
digital gene expression data. Bioinformatics, 26, 139–140.
34. Bailey,T.L. and Elkan,C. (1994) Proceedings of the Second
International Conference on Intelligent Systems for Molecular
Biology. AAAI Press, Menlo Park, California, pp. 28–36.
35. Crooks,G.E., Hon,G., Chandonia,J.-M. and Brenner,S.E. (2004)
WebLogo: a sequence logo generator. Genome Res., 14,
1188–1190.
36. Mahony,S. and Benos,P.V. (2007) STAMP: a web tool for
exploring DNA-binding motif similarities. Nucleic Acids Res., 35,
W253–W258.
37. Subramanian,A., Tamayo,P., Mootha,V.K., Mukherjee,S.,
Ebert,B.L., Gillette,M.A., Paulovich,A., Pomeroy,S.L.,
Golub,T.R., Lander,E.S. et al. (2005) Gene set enrichment
analysis: A knowledge-based approach for interpreting
genome-wide expression proﬁles. Proc. Natl Acad. Sci. USA., 102,
15545–15550.
38. Britos-Bray,M. and Friedman,A.D. (1997) Core binding factor
cannot synergistically activate the myeloperoxidase proximal
enhancer in immature myeloid cells without c-Myb.
Mol. Cell. Biol., 17, 5127–5135.
39. Oelgeschlager,M., Nuchprayoon,I., Luscher,B. and Friedman,A.D.
(1996) C/EBP, c-Myb, and PU.1 cooperate to regulate the
neutrophil elastase promoter. Mol. Cell. Biol., 16, 4717–4725.
40. Salomoni,P., Perrotti,D., Martinez,R., Franceschi,C. and
Calabretta,B. (1997) Resistance to apoptosis in CTLL-2 cells
constitutively expressing c-Myb is associated with induction of
BCL-2 expression and Myb-dependent regulation of bcl -2
promoter activity. Proc. Natl Acad. Sci. USA, 94, 3296–3301.
41. Taylor,D., Badiani,P. and Weston,K. (1996) A dominant
interfering Myb mutant causes apoptosis in T cells. Genes Dev.,
10, 2732–2744.
42. Drabsch,Y., Robert,R. and Gonda,T. (2010) MYB suppresses
differentiation and apoptosis of human breast cancer cells. Breast
Cancer Res., 12, R55.
43. The ENCODE Project Consortium. (2007) Identiﬁcation and
analysis of functional elements in 1% of the human genome by
the ENCODE pilot project. Nature, 447, 799–816.
44. Shapiro,L.H. (1995) Myb and ets proteins cooperate to
transactivate an early myeloid gene. J. Biol. Chem., 270,
8763–8771.
45. Reddy,M.A., Yang,B.S., Yue,X., Barnett,C.J., Ross,I.L.,
Sweet,M.J., Hume,D.A. and Ostrowski,M.C. (1994) Opposing
actions of c-ets/PU.1 and c-myb protooncogene products in
regulating the macrophage-speciﬁc promoters of the human
and mouse colony-stimulating factor-1 receptor (c-fms) genes.
J. Exp. Med., 180, 2309–2319.
46. Lutz,P.G., Houzel-Charavel,A., Moog-Lutz,C. and Cayre,Y.E.
(2001) Myeloblastin is an Myb target gene: mechanisms of
regulation in myeloid leukemia cells growth-arrested by retinoic
acid. Blood, 97, 2449–2456.
4678 Nucleic Acids Research, 2011,Vol.39, No. 1147. Peng,S., Lalani,S., Leavenworth,J.W., Ho,I.C. and Pauza,M.E.
(2007) c-Maf interacts with c-Myb to down-regulate Bcl-2
expression and increase apoptosis in peripheral CD4 cells.
Eur. J. Immunol., 37, 2868–2880.
48. Hegde,S.P., Zhao,J., Ashmun,R.A. and Shapiro,L.H. (1999)
c-Maf induces monocytic differentiation and apoptosis in bipotent
myeloid progenitors. Blood, 94, 1578–1589.
49. Hedge,S.P., Kumar,A., Kurschner,C. and Shapiro,L.H. (1998)
c-Maf interacts with c-Myb to regulate transcription of an early
myeloid gene during differentiation. Mol. Cell. Biol., 18,
2729–2737.
50. Tillmanns,S., Otto,C., Jaffray,E., DuRoure,C., Bakri,Y.,
Vanhille,L., Sarrazin,S., Hay,R.T. and Sieweke,M.H. (2007)
SUMO-modiﬁcation regulates MafB driven macrophage
differentiation by enabling Myb dependent transcriptional
repression. Mol. Cell. Biol., 27, 5554–5564.
51. Parker,D., Rivera,M., Zor,T., Henrion-Caude,A.,
Radhakrishnan,I., Kumar,A., Shapiro,L.H., Wright,P.E.,
Montminy,M. and Brindle,P.K. (1999) Role of secondary
structure in discrimination between constitutive and inducible
activators. Mol. Cell. Biol., 19, 5601–5607.
52. Dai,P., Akimaru,H., Tanaka,Y., Hou,D.X., Yasukawa,T.,
Kanei-Ishii,C., Takahashi,T. and Ishii,S. (1996) CBP as a
transcriptional coactivator of c-Myb. Genes Dev., 10, 528–540.
53. Kasper,L.H., Boussouar,F., Ney,P.A., Jackson,C.W., Rehg,J.,
van Deursen,J.M. and Brindle,P.K. (2002) A
transcription-factor-binding surface of coactivator p300 is required
for haematopoiesis. Nature, 419, 738–743.
54. Kauppi,M., Murphy,J.M., de Graaf,C.A., Hyland,C.D.,
Greig,K.T., Metcalf,D., Hilton,A.A., Nicola,N.A., Kile,B.T.,
Hilton,D.J. et al. (2008) Point mutation in the gene encoding
p300 suppresses thrombocytopenia in Mpl-/- mice. Blood, 112,
3148–3153.
55. Sandberg,M.L., Sutton,S.E., Pletcher,M.T., Wiltshire,T.,
Tarantino,L.M., Hogenesch,J.B. and Cooke,M.P. (2005) c-Myb
and p300 regulate hematopoietic stem cell proliferation and
differentiation. Dev. Cell, 8, 153–166.
56. Carpinelli,M.R., Hilton,D.J., Metcalf,D., Antonchuk,J.L.,
Hyland,C.D., Mifsud,S.L., Di Rago,L., Hilton,A.A., Willson,T.A.,
Roberts,A.W. et al. (2004) Suppressor screen in Mpl-/- mice:
c-Myb mutation causes supraphysiological production of platelets
in the absence of thrombopoietin signaling. Proc. Natl Acad.
Sci. USA, 101, 6553–6558.
57. Kalkhoven,E. (2004) CBP and p300: HATs for different
occasions. Biochem. Pharmacol., 68, 1145–1155.
58. Heintzman,N.D., Stuart,R.K., Hon,G., Fu,Y., Ching,C.W.,
Hawkins,R.D., Barrera,L.O., Van Calcar,S., Qu,C., Ching,K.A.
et al. (2007) Distinct and predictive chromatin signatures of
transcriptional promoters and enhancers in the human genome.
Nat. Genet., 39, 311–318.
59. Bhaumik,S.R., Smith,E. and Shilatifard,A. (2007) Covalent
modiﬁcations of histones during development and disease
pathogenesis. Nat. Struct. Mol. Biol., 14, 1008–1016.
60. Rosenbauer,F. and Tenen,D.G. (2007) Transcription factors in
myeloid development: balancing differentiation with
transformation. Nat. Rev. Immunol., 7, 105–117.
61. Kim,J., Chu,J., Shen,X., Wang,J. and Orkin,S.H. (2008) An
extended transcriptional network for pluripotency of embryonic
stem cells. Cell, 132, 1049–1061.
62. Hock,H., Hamblen,M.J., Rooke,H.M., Schindler,J.W., Saleque,S.,
Fujiwara,Y. and Orkin,S.H. (2004) Gﬁ-1 restricts proliferation
and preserves functional integrity of haematopoietic stem cells.
Nature, 431, 1002–1007.
63. Karsunky,H., Zeng,H., Schmidt,T., Zevnik,B., Kluge,R.,
Schmid,K.W., Duhrsen,U. and Moroy,T. (2002) Inﬂammatory
reactions and severe neutropenia in mice lacking the
transcriptional repressor Gﬁ1. Nat. Genet., 30, 295–300.
64. Georlette,D., Ahn,S., MacAlpine,D.M., Cheung,E., Lewis,P.W.,
Beall,E.L., Bell,S.P., Speed,T., Manak,J.R. and Botchan,M.R.
(2007) Genomic proﬁling and expression studies reveal both
positive and negative activities for the Drosophila Myb MuvB/
dREAM complex in proliferating cells. Genes Dev., 21,
2880–2896.
65. Tomaru,Y., Simon,C., Forrest,A., Miura,H., Kubosaki,A.,
Hayashizaki,Y. and Suzuki,M. (2009) Regulatory interdependence
of myeloid transcription factors revealed by Matrix RNAi
analysis. Genome Biol., 10, R121.
66. Weston,K. and Bishop,J.M. (1989) Transcriptional activation by
the v-myb oncogene and its cellular progenitor, c-myb. Cell, 58,
85–93.
67. Ganter,B. and Lipsick,J.S. (1997) Myb binding sites within the
N-ras promoter repress transcription. Oncogene, 15, 193–202.
68. Nomura,T., Tanikawa,J., Akimaru,H., Kanei-Ishii,C.,
Ichikawa-Iwata,E., Khan,M.M., Ito,H. and Ishii,S. (2004)
Oncogenic activation of c-Myb correlates with a loss of negative
regulation by TIF1beta and Ski. J. Biol. Chem., 279,
16715–16726.
69. Mizuguchi,G., Kanei-Ishii,C., Takahashi,T., Yasukawa,T.,
Nagase,T., Horikoshi,M., Yamamoto,T. and Ishii,S. (1995) c-Myb
Repression of c- erbB-2 Transcription by Direct Binding to the
c- erbB-2 Promoter. J. Biol. Chem., 270, 9384–9389.
70. Lee,K., Crowe,A. and Barton,M. (1999) p53-mediated repression
of alpha-fetoprotein gene expression by speciﬁc DNA binding.
Mol. Cell. Biol., 19, 1279–1288.
71. Jacquier,A. (2009) The complex eukaryotic transcriptome:
unexpected pervasive transcription and novel small RNAs.
Nat. Rev. Genet., 10, 833–844.
72. Chen,C.-Z., Li,L., Lodish,H.F. and Bartel,D.P. (2004)
MicroRNAs modulate hematopoietic lineage differentiation.
Science, 303, 83–86.
73. Alcalay,M., Tiacci,E., Bergomas,R., Bigerna,B., Venturini,E.,
Minardi,S.P., Meani,N., Diverio,D., Bernard,L., Tizzoni,L. et al.
(2005) Acute myeloid leukemia bearing cytoplasmic
nucleophosmin (NPMc+ AML) shows a distinct gene expression
proﬁle characterized by up-regulation of genes involved in
stem-cell maintenance. Blood, 106, 899–902.
74. Ross,M.E., Mahfouz,R., Onciu,M., Liu,H.-C., Zhou,X., Song,G.,
Shurtleff,S.A., Pounds,S., Cheng,C., Ma,J. et al. (2004) Gene
expression proﬁling of pediatric acute myelogenous leukemia.
Blood, 104, 3679–3687.
75. Rhodes,D.R., Yu,J., Shanker,K., Deshpande,N., Varambally,R.,
Ghosh,D., Barrette,T., Pandey,A. and Chinnaiyan,A.M. (2004)
Large-scale meta-analysis of cancer microarray data
identiﬁes common transcriptional proﬁles of neoplastic
transformation and progression. Proc. Natl Acad. Sci. USA, 101,
9309–9314.
76. Ivanova,N.B., Dimos,J.T., Schaniel,C., Hackney,J.A., Moore,K.A.
and Lemischka,I.R. (2002) A stem cell molecular signature.
Science, 298, 601–604.
77. Brown,A.L., Wilkinson,C.R., Waterman,S.R., Kok,C.H.,
Salerno,D.G., Diakiw,S.M., Reynolds,B., Scott,H.S., Tsykin,A.,
Glonek,G.F. et al. (2006) Genetic regulators of myelopoiesis and
leukemic signaling identiﬁed by gene proﬁling and linear
modeling. J. Leukoc. Biol., 80, 433–447.
78. Ashburner,M., Ball,C.A., Blake,J.A., Botstein,D., Butler,H.,
Cherry,J.M., Davis,A.P., Dolinski,K., Dwight,S.S., Eppig,J.T.
et al. (2000) Gene ontology: tool for the uniﬁcation
of biology. The Gene Ontology Consortium. Nat. Genet., 25,
25–29.
79. Lian,Z., Wang,L., Yamaga,S., Bonds,W., Beazer-Barclay,Y.,
Kluger,Y., Gerstein,M., Newburger,P.E., Berliner,N. and
Weissman,S.M. (2001) Genomic and proteomic analysis of the
myeloid differentiation program. Blood, 98, 513–524.
Nucleic Acids Research, 2011,Vol.39, No. 11 4679